144 ·Filed Jun 15, 2026

RVMD

Revolution Medicines, Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed3mo ago SEC0001950047-26-006148
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

The 10b5-1 plan removes timing suspicion — this is a scheduled monetization of option exercises, not a conviction sell signal. The filing is routine for an insider with large equity grants. Monitor for any filings that accelerate or expand the plan, but no trading action warranted on this notice alone.

DirectionNeutral
Confidencemedium
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
RVMD ▲ +29.87% at T+60d
NEUTRAL call ✓ call won +29.87% · α vs SPY +28.87% · entry $156.58 → $203.35
Entry anchored
Jun 15, 03:59 PM ET
via exchange tick
T+1d
+0.76%
call +0.76% · α +2.01%
$157.77
settled 4mo ago
T+5d
+8.26%
call +8.26% · α +10.49%
$169.51
settled 3mo ago
T+20d
+18.13%
call +18.13% · α +17.93%
$184.97
settled 3mo ago
T+60d
+29.87%
call +29.87% · α +28.87%
$203.35
settled 22d ago

Price Chart

Loading chart...

Executive Summary

Margaret A. Horn, an officer at Revolution Medicines, filed a Form 144 to sell 90,000 common shares (~$13.85M at filing price). The sale is pursuant to a Rule 10b5-1 plan, with shares acquired upon exercise of stock options. The advance notice signals planned monetization of equity compensation, not an opportunistic sale.

Key Facts

  • Insider: Margaret A. Horn (Officer)
  • Shares proposed for sale: 90,000 common shares
  • Estimated value: approx. $13.85 million ($153.87 per share)
  • Sale plan: Rule 10b5-1 trading arrangement adopted March 12, 2026
  • Prior sale on June 11, 2026: 10,000 shares for ~$1.48M
  • Prior sale on March 17, 2026: 4,583 shares for ~$455.9K
  • Shares are from option exercises — not open-market holdings

Financial Impact

Proposed sale of $13.85M (0.04% of $32.7B market cap). Minimal dilution/supply impact.

dilutioninsider holdings

Risk Factors

  • If subsequent open-market sales accelerate beyond the plan, it could signal insider caution
  • Insider has already sold ~$1.9M in June 2026 under the plan, consistent with routine diversification

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
96% bullish (27 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-006148
Document: 0001950047-26-006148-index.html0001950047-26-006148
Document: 0001950047-26-006148.txt0001950047-26-006148
26 reports for RVMD
Performance horizon
100% Hit rate 12 of 12 directional calls best @ T+60▲ +31.56%Apr 21, 2026
Filters
Rows
Reports for RVMD — sortable, filterable
TypeNow
Sep 15, 2026
16d ago
144
NEUTRAL ★ 2/10
$195.92 $190.74▼ −2.64%▼ −5.21%$206.54 (+5.42%)
Sep 15, 2026
16d ago
144
NEUTRAL ★ 4/10
$195.92 $190.74▼ −2.64%▼ −5.21%$206.54 (+5.42%)
Sep 15, 2026
17d ago
Insider Cluster
NEUTRAL ★ 2/10
$204.86 $190.95▼ −6.79%▼ −7.61%$206.54 (+0.82%)
Sep 14, 2026
17d ago
Insider Cluster
NEUTRAL ★ 3/10
$204.86 $192.86▼ −5.86%▼ −7.98%$206.54 (+0.82%)
Aug 26, 2026
5w ago
8-K
BULLISH ★ 8/10
$215.44 $209.23▼ −2.88%▼ −2.76%$206.54 (−4.13%)
Aug 26, 2026
5w ago
Press Release
BULLISH ★ 8/10
$215.44 $209.23▼ −2.88%▼ −2.76%$206.54 (−4.13%)
Aug 25, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$211.38 $209.87▼ −0.71%▼ −0.18%$206.54 (−2.29%)
Jul 2, 2026
13w ago
Press Release
BULLISH ★ 7/10
$189.24 $191.13▲ +1.00%▲ +0.07%$206.54 (+9.14%)
Jul 1, 2026
13w ago
Insider Cluster
NEUTRAL ★ 2/10
$187.51 $190.46▲ +1.57%▲ +1.31%$206.54 (+10.15%)
Jun 22, 2026
14w ago
8-K
NEUTRAL ★ 2/10
$165.81 $192.62▲ +16.17%▲ +16.62%$206.54 (+24.56%)
Showing 10 of 26

US Market Status

Market Open — Closes in 2h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access